Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Yale University
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
SWOG Cancer Research Network
M.D. Anderson Cancer Center
GOG Foundation
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center